Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2017

Open Access 01-12-2017 | Research article

Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis

Authors: Shi-Qin Wang, Li-Wei Zhang, Pan Wei, Hong Hua

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Login to get access

Abstract

Background

To systematically review and assess the efficacy and safety of hydroxychloroquine (HCQ) for treating primary Sjogren’s syndrome (pSS).

Methods

Five electronic databases (Pubmed, EMBASE, Web of science, Ovid, Cochrane Library) were searched for randomized controlled trials and retrospective or prospective studies published in English that reported the effect of HCQ on pSS. The subjective symptoms (sicca symptoms, fatigue and pain) and the objective indexes (erythrocyte sedimentation rate and Schirmer test) were assessed as main outcome measures. A meta-analysis and descriptive study on the efficacy and safety of HCQ were conducted. The estimate of the effect of HCQ treatment was expressed as a proportion together with 95% confidence interval, and plotted on a forest plot.

Results

Four trials with totals of 215 SS patients, including two randomized controlled trials, one double blind crossover trial and one retrospective open-label study, were analyzed in this review. For dry mouth and dry eyes, the effectiveness of HCQ treatment was essentially the same as placebo treatment. For fatigue, the effectiveness of HCQ was lower than placebo. The efficacy of HCQ in treating pain associated with pSS was superior to that of the placebo. There was no significant difference between HCQ-treated groups and controls in terms of Schirmer test results, but HCQ could reduce the erythrocyte sedimentation rate compare with placebo. A descriptive safety assessment showed that gastrointestinal adverse effects were the most common adverse effects associated with HCQ.

Conclusions

This systematic review showed that there is no significant difference between HCQ and placebo in the treatment of dry mouth and dry eye in pSS. Well-designed, randomized, controlled trials are needed to provide higher-quality evidence to confirm our findings, and future studies should focus on some other index or extraglandular measures, such as cutaneous manifestations, to further explore the therapeutic effect of HCQ in pSS.
Appendix
Available only for authorised users
Literature
1.
Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37(2):217–29.CrossRefPubMed
2.
Fox PC. Autoimmune diseases and Sjogren’s syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007;1098:15–21.CrossRefPubMed
3.
Espitia-Thibault A, Masseau A, Neel A, Espitia O, Toquet C, Mussini JM, Hamidou M. Sjogren’s syndrome-associated myositis with germinal centre-like structures. Autoimmun Rev. 2017;16(2):154–8.CrossRefPubMed
4.
5.
ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren’s Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum. 2011;40(6):547–51.CrossRefPubMed
6.
Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesti M, Tavoni A, et al. Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford, England). 2014;53(5):839–44.CrossRef
7.
Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, Theander E, Bombardieri S, et al. Characterization of systemic disease in primary Sjogren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford, England). 2015;54(12):2230–8.
8.
Fox RI. Sjogren’s syndrome. Lancet (London, England). 2005;366(9482):321–31.CrossRef
9.
Drosos AA, Andonopoulos AP, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM. Prevalence of primary Sjogren’s syndrome in an elderly population. Br J Rheumatol. 1988;27(2):123–7.CrossRefPubMed
10.
Venables PJ. Sjogren’s syndrome. Best Pract Res Clin Rheumatol. 2004;18(3):313–29.PubMed
11.
Chiorini JA, Cihakova D, Ouellette CE, Caturegli P. Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun. 2009;33(3-4):190–6.CrossRefPubMedPubMedCentral
12.
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983–9.CrossRefPubMed
13.
Goules AV, Tzioufas AG. Primary Sjgren’s syndrome: Clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev. 2016;15(7):695–703.CrossRefPubMed
14.
Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151–6.CrossRefPubMed
15.
Bostrom EA, d’Elia HF, Dahlgren U, Simark-Mattsson C, Hasseus B, Carlsten H, Tarkowski A, Bokarewa M. Salivary resistin reflects local inflammation in Sjogren’s syndrome. J Rheumatol. 2008;35(10):2005–11.PubMed
16.
Forsblad-d’Elia H, Carlsten H, Labrie F, Konttinen YT, Ohlsson C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren’s syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab. 2009;94(6):2044–51.CrossRefPubMed
17.
18.
19.
Alunno A, Carubbi F, Bartoloni E, Bistoni O, Caterbi S, Cipriani P, Giacomelli R, Gerli R. Unmasking the pathogenic role of IL-17 axis in primary Sjogren’s syndrome: a new era for therapeutic targeting? Autoimmun Rev. 2014;13(12):1167–73.CrossRefPubMed
20.
Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren’s syndrome. Curr Opin Rheumatol. 2007;19(5):406–13.CrossRefPubMed
21.
Verstappen GM, Kroese FG, Meiners PM, Corneth OB, Huitema MG, Haacke EA, van der Vegt B, Arends S, Vissink A, Bootsma H, et al. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjogren Syndrome. J Rheumatol. 2017;44(1):49–58.CrossRefPubMed
22.
Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H et al. Treatment Guidelines for Rheumatologic Manifestations of Sjogren’s: Use of Biologics, Management of Fatigue and Inflammatory Musculoskeletal Pain. Arthritis Care Res. 2017;69(4):517-27.
23.
Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. Jama. 2010;304(4):452–60.CrossRefPubMed
24.
Valim V, Trevisani VF, Pasoto SG, Serrano EV, Ribeiro SL, Fidelix TS, Vilela VS, Prado LL, Tanure LA, Liborio-Kimura TN, et al. Recommendations for the treatment of Sjogren’s syndrome. Rev Bras Reumatol. 2015;55(5):446–57.CrossRefPubMed
25.
Cornec D, Jamin C, Pers JO. Sjogren’s syndrome: where do we stand, and where shall we go? J Autoimmun. 2014;51:109–14.CrossRefPubMed
26.
Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjogren syndrome. Nat Rev Rheumatol. 2016;12(8):456–71.CrossRefPubMed
27.
Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum. 2015;44(6):627–32.CrossRefPubMed
28.
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231–69.CrossRefPubMed
29.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.CrossRefPubMed
30.
Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for rheumatoid arthritis. Cochrane Database of Syst Revi. 2000;(2):Cd000959.
31.
Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5 Suppl 1:S31–6.CrossRefPubMed
32.
Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren’s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58(4):253–6.CrossRefPubMedPubMedCentral
33.
Mumcu G, Bicakcigil M, Yilmaz N, Ozay H, Karacayli U, Cimilli H, Yavuz S. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren’s syndrome. Oral Health Prev Dent. 2013;11(3):229–34.PubMed
34.
Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ (Clin Res Ed). 2012;344:e3821.
35.
Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjogren’s syndrome. Nat Rev Rheumatol. 2012;8(7):399–411.CrossRefPubMed
36.
Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, Dubost JJ, Fauchais AL, Goeb V, Hachulla E, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8(5):e59868.CrossRefPubMedPubMedCentral
37.
Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360–4.CrossRefPubMedPubMedCentral
38.
Cankaya H, Alpoz E, Karabulut G, Guneri P, Boyacioglu H, Kabasakal Y. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjogren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(1):62–7.CrossRefPubMed
39.
Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. Jama. 2014;312(3):249–58.CrossRefPubMed
40.
Yoon CH, Lee HJ. Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjogren’s Syndrome: a Double-Blind Randomized Control Study. J Korean Med Sci. 2016;31(7):1127-35.
41.
Vivino FB, Carsons SE, Foulks G, Daniels TE, Parke A, Brennan MT, Forstot SL, Scofield RH, Hammitt KM. New Treatment Guidelines for Sjogren’s Disease. Rheum Dis Clin N Am. 2016;42(3):531–51.CrossRef
42.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clin Res Ed). 2015;349:g7647.
43.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.CrossRefPubMedPubMedCentral
44.
45.
Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951–7.CrossRefPubMed
46.
Heaton JM. The treatment of Sjogren’s syndrome with hydroxychloroquine. Am J Ophthalmol. 1963;55:982–6.CrossRef
47.
Senecal JL, Chartier S, Rothfield N. Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine. J Rheumatol. 1995;22(5):868–75.PubMed
48.
Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5 Suppl 1:S4–S10.CrossRefPubMed
49.
Pillemer SR, Pando J, Magno B, Kurrasch R, Atkinson J, Macynski A, Fox P. Hydroxychloroquine for Sjogren’s syndrome: A double-blind placebo controlled pilot trial. Arthritis Rheum. 1997;40(9 SUPPL):S203.
50.
Oxholm P, Prause JU, Schiodt M. Rational drug therapy - Recommendations for the treatment of patients with Sjogren’s syndrome. Drugs. 1998;56(3):345–53.CrossRefPubMed
51.
Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjogren’s syndrome with hydroxychloroquine. Am J Med. 1988;85(4a):62–7.CrossRefPubMed
52.
Yavuz S, Asfuroglu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome. Rheumatol Int. 2011;31(8):1045–9.CrossRefPubMed
Metadata
Title
Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis
Authors
Shi-Qin Wang
Li-Wei Zhang
Pan Wei
Hong Hua
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1543-z

Other articles of this Issue 1/2017

BMC Musculoskeletal Disorders 1/2017 Go to the issue

Research article

Hospital volume and the risk of revision in Oxford unicompartmental knee arthroplasty in the Nordic countries -an observational study of 14,496 cases

Research article

Slipped capital femoral epiphysis: a population-based study

Technical advance

Modifications to advanced Core decompression for treatment of Avascular necrosis of the femoral head

Research article

Comparison of semi-quantitative and quantitative dynamic contrast-enhanced MRI evaluations of vertebral marrow perfusion in a rat osteoporosis model

Research article

Measurement of acetabular inclination and anteversion via CT generated 3D pelvic model

Research article

Utilization of CT scanning associated with complex spine surgery